Category: Article

Dr. John Lewis Speaks on “How can I protect myself from prostate cancer?” on CBC Podcast The Dose

Natalia Hotsaliuk2024-11-02T21:10:41+00:00

Listen as Dr. John Lewis speaks on the CBC’s podcast The Dose by Dr. Brian Goldman: Prostate cancer is the most common cancer among Canadian men, with an estimated one in eight men expected to be diagnosed during their lifetime. John Lewis, a prostate cancer researcher and University of Alberta oncology professor, says better screening tools will help detect the disease more effectively in men.

LISTEN NOW

Dr. John Lewis Speaks on “How can I protect myself from prostate cancer?” on CBC Podcast The DoseNatalia Hotsaliuk2024-11-02T21:10:41+00:00

Sean Secord Speaks on Prostate Cancer Screening at PROSTAID

Natalia Hotsaliuk2024-10-25T20:02:49+00:00

Sean Secord had the opportunity to speak at PROSTAID’s monthly meeting in Calgary, where he discussed the importance of prostate cancer screening and the impact ClarityDX Prostate can have on patients’ lives. The group was very engaged and raised thoughtful questions around screening frequency, accuracy, and what the future of prostate health management could look like with ClarityDX Prostate.

WATCH ON YOUTUBE

Sean Secord Speaks on Prostate Cancer Screening at PROSTAIDNatalia Hotsaliuk2024-10-25T20:02:49+00:00

Nanostics Gets Featured on New Podcast by AIMSS

Natalia Hotsaliuk2024-10-16T19:45:34+00:00

Nanostics was excited to be the first to be featured on a new podcast by AIMSS, called ByteMed! Watch us delve into the transformative world of diagnostic technology. Discover how the innovative platform, ClarityDX®, harnesses advanced machine learning algorithms to create noninvasive disease risk scores, particularly in the realm of cancer detection.

Sean Secord and Robert Paproski from Nanostics Inc. had the chance to discuss the critical importance of early prostate cancer detection and how ClarityDX leverages machine learning to improve patient outcomes. They also shared some interesting insights—be sure to listen to the full conversation!

WATCH ON YOUTUBE

LISTEN ON SPOTIFY

Nanostics Gets Featured on New Podcast by AIMSSNatalia Hotsaliuk2024-10-16T19:45:34+00:00

Nanostics and OncoHelix Partner to Provide ClarityDX Prostate for Men at Risk of Having Aggressive Prostate Cancer in the Middle East

perrin2024-09-29T02:20:50+00:00

OncoHelix will now offer the validated ClarityDX Prostate Risk Score to healthcare providers and their patients suspected of having aggressive prostate cancer.
ClarityDX Prostate is a blood-based diagnostic tool that uses AI-powered learning to determine the risk of aggressive prostate cancer.

EDMONTON, Alberta & CALGARY, Alberta–Nanostics. Inc., a precision health company developing diagnostic tests with its ClarityDX® platform technology, and OncoHelix a leader in precision diagnostics, today announced their partnership to provide ClarityDX Prostate® to healthcare providers and men in the Middle East.

OncoHelix provides advanced molecular diagnostics and immune profile testing to the Middle East and North Africa (MENA) region through OncoHelix-coLAB, a state-of-the-art laboratory within Burjeel Medical City, Abu Dhabi. This facility is a joint venture between OncoHelix and Burjeel Holdings, one of the largest healthcare providers in the Middle East. The OncoHelix-coLAB facility will now also provide Nanostics’ ClarityDX Prostate diagnostic tool to men at risk of having aggressive prostate cancer. The addition of this test will further enhance patient diagnostics and treatment outcomes in the region.

“Partnering with OncoHelix, another Alberta-based company, to bring ClarityDX Prostate to men in the Middle East really shows how relevant Alberta-developed technology has become to the world,” said Dr. John Lewis, CEO of Nanostics and Bird Dogs Chair of Translational Oncology at the University of Alberta. “ClarityDX Prostate is a powerful diagnostic tool that can help identify men with aggressive prostate cancer early. We want all men to benefit from early detection leading to better outcomes.”

Press Release

Nanostics and OncoHelix Partner to Provide ClarityDX Prostate for Men at Risk of Having Aggressive Prostate Cancer in the Middle Eastperrin2024-09-29T02:20:50+00:00

Nanostics and Protean Launch CDX Prostate for Men at Risk of Having Aggressive Prostate Cancer in the US

perrin2024-09-29T02:23:12+00:00

EDMONTON, Alberta–Nanostics Inc., a precision health company developing diagnostic tests with its ClarityDX® platform technology, and Protean Biodiagnostics Inc. (Protean) today announced their partnership to provide CDX Prostate in the United States.

CDX Prostate uses biological data, clinical information, and AI-powered learning models to generate a risk score for aggressive prostate cancer, marking a significant advancement in prostate cancer screening. It provides critical support to men and their healthcare providers in making more informed decisions about whether to proceed with a biopsy following a high prostate-specific antigen (PSA) test result or an abnormal Digital Rectal Exam (DRE).

“This agreement with Protean is a huge milestone for Nanostics – we can now provide CDX Prostate to men in the US,” said Dr. John Lewis, CEO of Nanostics and Bird Dogs Chair of Translational Oncology at the University of Alberta. “When used as a reflex test, CDX Prostate is a powerful tool to help identify men with aggressive prostate cancer sooner, leading to better outcomes while also minimizing the negative effects associated with overdiagnosis of the disease.”

“At Protean, we are dedicated to providing access to the best-in-class precision medicine solutions,” said Dr. Anthony Magliocco, CEO of Protean BioDiagnostics. “We are excited to be able to provide CDX Prostate as part of our cancer screening program”.

Press Release

Nanostics and Protean Launch CDX Prostate for Men at Risk of Having Aggressive Prostate Cancer in the USperrin2024-09-29T02:23:12+00:00

Breakthrough test provides clarity for prostate cancer diagnosis

Natalia Hotsaliuk2024-09-09T21:55:20+00:00

With support from the Canadian Cancer Society, Dr John Lewis took his research to new heights with an innovative test for prostate cancer screening.

“This test can tell you if you have a low or high risk of aggressive prostate cancer,” Dr Lewis says. “It’s an addition to the PSA test and designed to give men and their doctors more clarity so they can make informed decisions about whether to proceed with a biopsy.”

Click below to read the full article.

Full Article

Breakthrough test provides clarity for prostate cancer diagnosisNatalia Hotsaliuk2024-09-09T21:55:20+00:00

Nanostics Gets Featured on Global News

Natalia Hotsaliuk2024-07-31T16:08:31+00:00

Prostate cancer is one of the most common cancers among men in Canada and early detection can save lives. See Nicole Stillger from Global News explain how ClarityDX Prostate works, and how support from Alberta Innovates helps advance our research.

Video

Nanostics Gets Featured on Global NewsNatalia Hotsaliuk2024-07-31T16:08:31+00:00

Research supporting ClarityDX Prostate published in Nature Digital Medicine

Natalia Hotsaliuk2024-07-03T19:51:25+00:00

Published 26 June 2024

Development of an effective predictive screening tool for prostate cancer using the ClarityDX machine learning platform

M. Eric Hyndman, Robert J. Paproski, Adam Kinnaird, Adrian Fairey, Leonard Marks, Christian P. Pavlovich, Sean A. Fletcher, Roman Zachoval, Vanda Adamcova, Jiri Stejskal, Armen Aprikian, Christopher J. D. Wallis, Desmond Pink, Catalina Vasquez, Perrin H. Beatty & John D. Lewis

Abstract

The current prostate cancer (PCa) screen test, prostate-specific antigen (PSA), has a high sensitivity for PCa but low specificity for high-risk, clinically significant PCa (csPCa), resulting in overdiagnosis and overtreatment of non-csPCa. Early identification of csPCa while avoiding unnecessary biopsies in men with non-csPCa is challenging. We built an optimized machine learning platform (ClarityDX) and showed its utility in generating models predicting csPCa. Integrating the ClarityDX platform with blood-based biomarkers for clinically significant PCa and clinical biomarker data from a 3448-patient cohort, we developed a test to stratify patients’ risk of csPCa; called ClarityDX Prostate. When predicting high risk cancer in the validation cohort, ClarityDX Prostate showed 95% sensitivity, 35% specificity, 54% positive predictive value, and 91% negative predictive value, at a ≥ 25% threshold. Using ClarityDX Prostate at this threshold could avoid up to 35% of unnecessary prostate biopsies. ClarityDX Prostate showed higher accuracy for predicting the risk of csPCa than PSA alone and the tested model-based risk calculators. Using this test as a reflex test in men with elevated PSA levels may help patients and their healthcare providers decide if a prostate biopsy is necessary.

Full Article

Research supporting ClarityDX Prostate published in Nature Digital MedicineNatalia Hotsaliuk2024-07-03T19:51:25+00:00

Nanostics Prostate Cancer Screening Test, ClarityDX Prostate®, becomes accessible to men in British Columbia, Saskatchewan, and Ontario

perrin2024-06-05T14:30:41+00:00

EDMONTON, AB, June 5, 2024 /CNW/ – Nanostics Inc., a precision health company developing diagnostic tests with its ClarityDX® platform technology, is thrilled to announce today that men can now provide blood samples for its ClarityDX Prostate test at LifeLabs collection sites across British Columbia, Saskatchewan, and Ontario.

ClarityDX Prostate uses biological data, clinical information, and machine learning models to generate a risk score for aggressive prostate cancer, marking a significant advancement in prostate cancer screening. It provides critical support to men and their healthcare providers in making more informed decisions about whether to proceed with a biopsy or not following a high prostate-specific antigen (PSA) test result.

“We are very happy that we can now bring a powerful tool in prostate cancer screening to men and their healthcare providers in BC, Saskatchewan, and Ontario“, said Dr. John Lewis, CEO of Nanostics and Bird Dogs Chair of Translational Oncology at the University of Alberta. “When a doctor orders this test for their patient, they will receive accurate information about his risk of aggressive prostate cancer, helping make informed treatment decisions and avoid unnecessary invasive prostate biopsies.”

ClarityDX Prostate is available in British Columbia, Saskatchewan, and Ontario as a laboratory-developed test from Nanostics Clinical Laboratory in Edmonton, Alberta. In these provinces, tests are ordered, analyzed, and reported to the prescribing healthcare provider by Nanostics.

Go to www.nanosticsdx.com for more information and to order ClarityDX Prostate. Please direct all inquiries about the ClarityDX Prostate test to Nanostics via email at [email protected] or telephone 1-800-672-2027. ClarityDX Prostate is also available in Alberta from Nanostics as well as in Quebec from CDL Laboratories.

Click on the link below to read the full press release.

Press Release English

Nanostics Prostate Cancer Screening Test, ClarityDX Prostate®, becomes accessible to men in British Columbia, Saskatchewan, and Ontarioperrin2024-06-05T14:30:41+00:00

Nanostics partners with CDL Laboratories to Provide Access to ClarityDX Prostate for Men at Risk of Having Aggressive Prostate Cancer

perrin2024-05-22T12:15:29+00:00

Quebec-based CDL Laboratories will now offer the validated ClarityDX Prostate risk score to healthcare providers and their patients suspected of having aggressive prostate cancer.
ClarityDX Prostate combines biological and clinical information using AI-powered learning to generate a risk score for aggressive prostate cancer.

EDMONTON, ALBERTA – May 22 – Nanostics Inc., a precision health company developing diagnostic tests with its ClarityDX® platform technology, signed an agreement with Quebec-based CDL Laboratories (CDL) to expand access to the ClarityDX Prostate® to men and their healthcare providers.

ClarityDX Prostate uses biological data, clinical information, and AI-powered learning models to generate a risk score for aggressive prostate cancer, marking a significant advancement in prostate cancer screening. It provides critical support to men and their healthcare providers in making more informed decisions about whether to proceed with a biopsy or not following a high prostate-specific antigen (PSA) test result.

Click on the link below to read the full press release.

Press Release English

Press Release French

Nanostics partners with CDL Laboratories to Provide Access to ClarityDX Prostate for Men at Risk of Having Aggressive Prostate Cancerperrin2024-05-22T12:15:29+00:00

Follow Us

Contact Us